Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Our aim is to develop new and improved therapies that offer benefits over existing treatment options
Roche has a portfolio of therapies for the treatment of cancer as well as diseases including haemophilia, central nervous system disorders, lung disorders and inflammatory diseases.
Our products currently supported on rocheresources.co.uk
Prescribing Information
TECENTRIQ®▼(atezolizumab) Great Britain
TECENTRIQ®(atezolizumab) Northern Ireland
▼Tecentriq is subject to additional monitoring in Great Britain. In Northern Ireland, a black triangle is not required for Tecentriq and it is not subject to additional monitoring.
Further Information
Congress and Meetings
Highlights from the latest international and national congresses and Roche-organised meetings.
Abbreviartions
IV, intravenous; SC, subcutaneous;
M-GB-00007409
Date of preparation: May 2022